Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.
Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investors' optimism continues to be high on solid prospects of Hill-Rom Holdings (HRC).
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.
Here's Why You Should Consider Betting on CONMED Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Henry Schein Expands SolutionsHub With CueSquared MobilePay
by Zacks Equity Research
The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.
Ecolab (ECL) Expands Product Portfolio With New Technology
by Zacks Equity Research
Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors' confidence continues to be high on ResMed's (RMD) prospects.
Haemonetics Rides on Strong Plasma and Global Expansion
by Zacks Equity Research
Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).
Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results
by Zacks Equity Research
This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.
Medtronic (MDT) Benefits from Strength Across Business Groups
by Zacks Equity Research
Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Here's Why You Should Invest in NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investor confidence is currently high on NuVasive's (NUVA) prospects.
Edwards Lifesciences Sapien 3 System Recall Classified Class I
by Zacks Equity Research
Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Invest in DaVita (DVA) Stock For Now
by Zacks Equity Research
DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.
Here's Why You Should Retain Nevro (NVRO) in Your Portfolio
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Here's Why You Should Retain Wright Medical Stock For Now
by Zacks Equity Research
Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space. However, forex remains a woe.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Outlook for Outpatient and Home Healthcare Industry Looks Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.
Moving Average Crossover Alert: Amedisys
by Zacks Equity Research
Amedisys, Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.